nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Dacarbazine—sarcoma	0.0907	0.287	CbGbCtD
Bortezomib—PTGS1—Etoposide—sarcoma	0.0444	0.141	CbGbCtD
Bortezomib—CYP1A2—Dacarbazine—sarcoma	0.0405	0.128	CbGbCtD
Bortezomib—CYP3A4—Thiotepa—sarcoma	0.0383	0.121	CbGbCtD
Bortezomib—CYP2C8—Etoposide—sarcoma	0.0256	0.0811	CbGbCtD
Bortezomib—CYP1A2—Etoposide—sarcoma	0.0198	0.0628	CbGbCtD
Bortezomib—CYP3A4—Mitoxantrone—sarcoma	0.0165	0.0522	CbGbCtD
Bortezomib—CYP3A4—Vincristine—sarcoma	0.0113	0.0359	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—sarcoma	0.0111	0.0353	CbGbCtD
Bortezomib—CYP3A4—Etoposide—sarcoma	0.0104	0.0329	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—sarcoma	0.00708	0.0224	CbGbCtD
Bortezomib—PSMD1—mammary gland—sarcoma	0.00384	0.0218	CbGeAlD
Bortezomib—PSMD2—mammary gland—sarcoma	0.0034	0.0193	CbGeAlD
Bortezomib—CTSG—myometrium—sarcoma	0.00338	0.0192	CbGeAlD
Bortezomib—PSMA1—embryo—sarcoma	0.00312	0.0177	CbGeAlD
Bortezomib—CTSG—seminal vesicle—sarcoma	0.00305	0.0174	CbGeAlD
Bortezomib—CTSG—hematopoietic system—sarcoma	0.0029	0.0165	CbGeAlD
Bortezomib—CTSG—connective tissue—sarcoma	0.00279	0.0159	CbGeAlD
Bortezomib—PSMA1—hematopoietic system—sarcoma	0.00279	0.0158	CbGeAlD
Bortezomib—PSMD1—myometrium—sarcoma	0.00272	0.0155	CbGeAlD
Bortezomib—PSMA1—connective tissue—sarcoma	0.00268	0.0152	CbGeAlD
Bortezomib—PSMB2—mammary gland—sarcoma	0.00255	0.0145	CbGeAlD
Bortezomib—CTSG—skin of body—sarcoma	0.00252	0.0143	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vincristine—sarcoma	0.00252	0.5	CbGdCrCtD
Bortezomib—PSMB8—Podofilox—Etoposide—sarcoma	0.00252	0.5	CbGdCrCtD
Bortezomib—PSMD1—seminal vesicle—sarcoma	0.00246	0.014	CbGeAlD
Bortezomib—PSMA1—skin of body—sarcoma	0.00242	0.0138	CbGeAlD
Bortezomib—PSMD2—myometrium—sarcoma	0.00241	0.0137	CbGeAlD
Bortezomib—PSMB8—myometrium—sarcoma	0.0024	0.0136	CbGeAlD
Bortezomib—PSMD2—embryo—sarcoma	0.00232	0.0132	CbGeAlD
Bortezomib—CTSG—cardiac atrium—sarcoma	0.0022	0.0125	CbGeAlD
Bortezomib—PSMD2—seminal vesicle—sarcoma	0.00218	0.0124	CbGeAlD
Bortezomib—PSMB8—seminal vesicle—sarcoma	0.00217	0.0123	CbGeAlD
Bortezomib—PSMB5—myometrium—sarcoma	0.00212	0.012	CbGeAlD
Bortezomib—PSMA1—uterus—sarcoma	0.0021	0.012	CbGeAlD
Bortezomib—PSMD2—hematopoietic system—sarcoma	0.00207	0.0118	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—sarcoma	0.00206	0.0117	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—sarcoma	0.00204	0.0116	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—sarcoma	0.00196	0.0111	CbGeAlD
Bortezomib—CTSG—tendon—sarcoma	0.00192	0.0109	CbGeAlD
Bortezomib—PSMB5—seminal vesicle—sarcoma	0.00191	0.0109	CbGeAlD
Bortezomib—CTSG—bone marrow—sarcoma	0.00186	0.0106	CbGeAlD
Bortezomib—PSMB1—myometrium—sarcoma	0.00185	0.0105	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—sarcoma	0.00182	0.0104	CbGeAlD
Bortezomib—PSMB2—myometrium—sarcoma	0.00181	0.0103	CbGeAlD
Bortezomib—PSMD2—skin of body—sarcoma	0.0018	0.0102	CbGeAlD
Bortezomib—PSMA1—bone marrow—sarcoma	0.00179	0.0102	CbGeAlD
Bortezomib—PSMB1—embryo—sarcoma	0.00178	0.0101	CbGeAlD
Bortezomib—PSMD1—cardiac atrium—sarcoma	0.00178	0.0101	CbGeAlD
Bortezomib—PSMD1—uterus—sarcoma	0.00177	0.01	CbGeAlD
Bortezomib—PSMB2—embryo—sarcoma	0.00174	0.00988	CbGeAlD
Bortezomib—PSMB1—seminal vesicle—sarcoma	0.00167	0.00951	CbGeAlD
Bortezomib—PSMB2—seminal vesicle—sarcoma	0.00163	0.00928	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—sarcoma	0.0016	0.00911	CbGeAlD
Bortezomib—CTSG—testis—sarcoma	0.00159	0.00904	CbGeAlD
Bortezomib—PSMB1—hematopoietic system—sarcoma	0.00159	0.00904	CbGeAlD
Bortezomib—PSMD2—cardiac atrium—sarcoma	0.00157	0.00894	CbGeAlD
Bortezomib—PSMD2—uterus—sarcoma	0.00156	0.0089	CbGeAlD
Bortezomib—SLC31A1—myometrium—sarcoma	0.00156	0.00889	CbGeAlD
Bortezomib—PSMB2—hematopoietic system—sarcoma	0.00155	0.00882	CbGeAlD
Bortezomib—PSMD1—tendon—sarcoma	0.00155	0.0088	CbGeAlD
Bortezomib—PSMA1—testis—sarcoma	0.00153	0.00868	CbGeAlD
Bortezomib—PSMD1—bone marrow—sarcoma	0.0015	0.00852	CbGeAlD
Bortezomib—PSMB2—connective tissue—sarcoma	0.00149	0.00849	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—sarcoma	0.00146	0.00829	CbGeAlD
Bortezomib—PSMA1—liver—sarcoma	0.00144	0.0082	CbGeAlD
Bortezomib—SLC31A1—seminal vesicle—sarcoma	0.00141	0.00803	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—sarcoma	0.0014	0.00796	CbGeAlD
Bortezomib—PSMB1—skin of body—sarcoma	0.00138	0.00786	CbGeAlD
Bortezomib—PSMB5—cardiac atrium—sarcoma	0.00138	0.00785	CbGeAlD
Bortezomib—PSMB5—uterus—sarcoma	0.00137	0.00781	CbGeAlD
Bortezomib—PSMD2—tendon—sarcoma	0.00137	0.00779	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—sarcoma	0.00137	0.00777	CbGeAlD
Bortezomib—PSMB8—tendon—sarcoma	0.00136	0.00775	CbGeAlD
Bortezomib—PSMB2—skin of body—sarcoma	0.00135	0.00767	CbGeAlD
Bortezomib—PSMD2—bone marrow—sarcoma	0.00133	0.00755	CbGeAlD
Bortezomib—PSMB8—bone marrow—sarcoma	0.00132	0.0075	CbGeAlD
Bortezomib—PSMD1—testis—sarcoma	0.00128	0.00729	CbGeAlD
Bortezomib—PSMD1—liver—sarcoma	0.00121	0.00689	CbGeAlD
Bortezomib—PSMB1—cardiac atrium—sarcoma	0.00121	0.00686	CbGeAlD
Bortezomib—PSMB5—tendon—sarcoma	0.0012	0.00684	CbGeAlD
Bortezomib—PSMB1—uterus—sarcoma	0.0012	0.00683	CbGeAlD
Bortezomib—PSMB2—cardiac atrium—sarcoma	0.00118	0.0067	CbGeAlD
Bortezomib—PSMB2—uterus—sarcoma	0.00117	0.00666	CbGeAlD
Bortezomib—PSMB5—bone marrow—sarcoma	0.00117	0.00663	CbGeAlD
Bortezomib—CTSG—lymph node—sarcoma	0.00115	0.00655	CbGeAlD
Bortezomib—PSMD2—testis—sarcoma	0.00114	0.00645	CbGeAlD
Bortezomib—PSMB8—testis—sarcoma	0.00113	0.00641	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—sarcoma	0.00112	0.00636	CbGeAlD
Bortezomib—PSMA1—lymph node—sarcoma	0.00111	0.00629	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—sarcoma	0.00109	0.00621	CbGeAlD
Bortezomib—PSMD2—liver—sarcoma	0.00107	0.0061	CbGeAlD
Bortezomib—PSMB8—liver—sarcoma	0.00107	0.00606	CbGeAlD
Bortezomib—PSMB1—tendon—sarcoma	0.00105	0.00598	CbGeAlD
Bortezomib—PSMB2—tendon—sarcoma	0.00103	0.00584	CbGeAlD
Bortezomib—SLC31A1—cardiac atrium—sarcoma	0.00102	0.0058	CbGeAlD
Bortezomib—PSMB1—bone marrow—sarcoma	0.00102	0.00579	CbGeAlD
Bortezomib—PSMB5—testis—sarcoma	0.000997	0.00567	CbGeAlD
Bortezomib—PSMB2—bone marrow—sarcoma	0.000994	0.00565	CbGeAlD
Bortezomib—PSMB5—liver—sarcoma	0.000942	0.00536	CbGeAlD
Bortezomib—PSMD1—lymph node—sarcoma	0.000929	0.00528	CbGeAlD
Bortezomib—SLC31A1—tendon—sarcoma	0.000889	0.00505	CbGeAlD
Bortezomib—PSMB1—testis—sarcoma	0.000871	0.00495	CbGeAlD
Bortezomib—SLC31A1—bone marrow—sarcoma	0.000861	0.0049	CbGeAlD
Bortezomib—PSMB2—testis—sarcoma	0.00085	0.00483	CbGeAlD
Bortezomib—PSMB1—liver—sarcoma	0.000824	0.00468	CbGeAlD
Bortezomib—PSMD2—lymph node—sarcoma	0.000823	0.00468	CbGeAlD
Bortezomib—PSMB8—lymph node—sarcoma	0.000818	0.00465	CbGeAlD
Bortezomib—PTGS1—endothelium—sarcoma	0.000816	0.00464	CbGeAlD
Bortezomib—CYP2C8—mammary gland—sarcoma	0.000811	0.00461	CbGeAlD
Bortezomib—PSMB2—liver—sarcoma	0.000804	0.00457	CbGeAlD
Bortezomib—SLC31A1—testis—sarcoma	0.000736	0.00418	CbGeAlD
Bortezomib—PSMB5—lymph node—sarcoma	0.000722	0.00411	CbGeAlD
Bortezomib—CYP2C9—mammary gland—sarcoma	0.000721	0.0041	CbGeAlD
Bortezomib—SLC31A1—liver—sarcoma	0.000696	0.00396	CbGeAlD
Bortezomib—PSMB1—lymph node—sarcoma	0.000632	0.00359	CbGeAlD
Bortezomib—PSMB2—lymph node—sarcoma	0.000616	0.0035	CbGeAlD
Bortezomib—CYP2C19—hematopoietic system—sarcoma	0.000566	0.00322	CbGeAlD
Bortezomib—SLC31A1—lymph node—sarcoma	0.000534	0.00303	CbGeAlD
Bortezomib—CYP2C8—hematopoietic system—sarcoma	0.000494	0.00281	CbGeAlD
Bortezomib—CYP1A2—hematopoietic system—sarcoma	0.000463	0.00263	CbGeAlD
Bortezomib—CYP1A1—hematopoietic system—sarcoma	0.000456	0.00259	CbGeAlD
Bortezomib—CYP2C9—hematopoietic system—sarcoma	0.000439	0.0025	CbGeAlD
Bortezomib—PTGS1—seminal vesicle—sarcoma	0.000422	0.0024	CbGeAlD
Bortezomib—PTGS1—hematopoietic system—sarcoma	0.000401	0.00228	CbGeAlD
Bortezomib—CYP1A1—skin of body—sarcoma	0.000397	0.00225	CbGeAlD
Bortezomib—PTGS1—connective tissue—sarcoma	0.000386	0.00219	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—sarcoma	0.000353	0.00201	CbGeAlD
Bortezomib—PTGS1—skin of body—sarcoma	0.000348	0.00198	CbGeAlD
Bortezomib—CYP1A1—cardiac atrium—sarcoma	0.000346	0.00197	CbGeAlD
Bortezomib—CYP1A1—uterus—sarcoma	0.000345	0.00196	CbGeAlD
Bortezomib—CYP3A4—hematopoietic system—sarcoma	0.000335	0.0019	CbGeAlD
Bortezomib—CYP2D6—hematopoietic system—sarcoma	0.000329	0.00187	CbGeAlD
Bortezomib—PTGS1—cardiac atrium—sarcoma	0.000304	0.00173	CbGeAlD
Bortezomib—PTGS1—uterus—sarcoma	0.000303	0.00172	CbGeAlD
Bortezomib—CYP2C19—liver—sarcoma	0.000293	0.00167	CbGeAlD
Bortezomib—CYP2C8—testis—sarcoma	0.000271	0.00154	CbGeAlD
Bortezomib—PTGS1—tendon—sarcoma	0.000265	0.00151	CbGeAlD
Bortezomib—CYP2C8—liver—sarcoma	0.000256	0.00146	CbGeAlD
Bortezomib—CYP1A2—liver—sarcoma	0.00024	0.00136	CbGeAlD
Bortezomib—CYP1A1—liver—sarcoma	0.000236	0.00134	CbGeAlD
Bortezomib—CYP2C9—liver—sarcoma	0.000227	0.00129	CbGeAlD
Bortezomib—PTGS1—testis—sarcoma	0.00022	0.00125	CbGeAlD
Bortezomib—CYP1A1—lymph node—sarcoma	0.000181	0.00103	CbGeAlD
Bortezomib—CYP2D6—testis—sarcoma	0.000181	0.00103	CbGeAlD
Bortezomib—CYP3A4—liver—sarcoma	0.000173	0.000986	CbGeAlD
Bortezomib—CYP2D6—liver—sarcoma	0.000171	0.00097	CbGeAlD
Bortezomib—PTGS1—lymph node—sarcoma	0.000159	0.000905	CbGeAlD
Bortezomib—Pancreatitis—Doxorubicin—sarcoma	0.000107	0.000325	CcSEcCtD
Bortezomib—Weight decreased—Epirubicin—sarcoma	0.000106	0.000324	CcSEcCtD
Bortezomib—Dyspnoea—Etoposide—sarcoma	0.000106	0.000324	CcSEcCtD
Bortezomib—Hyperglycaemia—Epirubicin—sarcoma	0.000106	0.000323	CcSEcCtD
Bortezomib—Angina pectoris—Doxorubicin—sarcoma	0.000106	0.000323	CcSEcCtD
Bortezomib—Hypersensitivity—Mitoxantrone—sarcoma	0.000106	0.000322	CcSEcCtD
Bortezomib—Asthenia—Vincristine—sarcoma	0.000106	0.000322	CcSEcCtD
Bortezomib—Vomiting—Thiotepa—sarcoma	0.000106	0.000322	CcSEcCtD
Bortezomib—Pneumonia—Epirubicin—sarcoma	0.000105	0.000321	CcSEcCtD
Bortezomib—Infestation—Epirubicin—sarcoma	0.000105	0.00032	CcSEcCtD
Bortezomib—Infestation NOS—Epirubicin—sarcoma	0.000105	0.00032	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—sarcoma	0.000105	0.000319	CcSEcCtD
Bortezomib—Rash—Thiotepa—sarcoma	0.000105	0.000319	CcSEcCtD
Bortezomib—Bronchitis—Doxorubicin—sarcoma	0.000105	0.000319	CcSEcCtD
Bortezomib—Dermatitis—Thiotepa—sarcoma	0.000105	0.000319	CcSEcCtD
Bortezomib—Headache—Thiotepa—sarcoma	0.000104	0.000317	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000104	0.000317	CcSEcCtD
Bortezomib—Rash—Dactinomycin—sarcoma	0.000104	0.000317	CcSEcCtD
Bortezomib—Decreased appetite—Etoposide—sarcoma	0.000104	0.000316	CcSEcCtD
Bortezomib—Pancytopenia—Doxorubicin—sarcoma	0.000103	0.000315	CcSEcCtD
Bortezomib—Renal failure—Epirubicin—sarcoma	0.000103	0.000314	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Etoposide—sarcoma	0.000103	0.000314	CcSEcCtD
Bortezomib—Asthenia—Mitoxantrone—sarcoma	0.000103	0.000314	CcSEcCtD
Bortezomib—Fatigue—Etoposide—sarcoma	0.000103	0.000313	CcSEcCtD
Bortezomib—Neuropathy peripheral—Epirubicin—sarcoma	0.000103	0.000313	CcSEcCtD
Bortezomib—Stomatitis—Epirubicin—sarcoma	0.000102	0.000311	CcSEcCtD
Bortezomib—Constipation—Etoposide—sarcoma	0.000102	0.000311	CcSEcCtD
Bortezomib—Pain—Etoposide—sarcoma	0.000102	0.000311	CcSEcCtD
Bortezomib—Urinary tract infection—Epirubicin—sarcoma	0.000102	0.000311	CcSEcCtD
Bortezomib—Conjunctivitis—Epirubicin—sarcoma	0.000102	0.000311	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—sarcoma	0.000102	0.00031	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000101	0.000308	CcSEcCtD
Bortezomib—Diarrhoea—Vincristine—sarcoma	0.000101	0.000307	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—sarcoma	0.000101	0.000306	CcSEcCtD
Bortezomib—Haematuria—Epirubicin—sarcoma	0.0001	0.000305	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—sarcoma	9.93e-05	0.000303	CcSEcCtD
Bortezomib—Hepatobiliary disease—Epirubicin—sarcoma	9.92e-05	0.000302	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—sarcoma	9.9e-05	0.000302	CcSEcCtD
Bortezomib—Epistaxis—Epirubicin—sarcoma	9.89e-05	0.000301	CcSEcCtD
Bortezomib—Nausea—Thiotepa—sarcoma	9.87e-05	0.000301	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—sarcoma	9.85e-05	0.0003	CcSEcCtD
Bortezomib—Sinusitis—Epirubicin—sarcoma	9.84e-05	0.0003	CcSEcCtD
Bortezomib—Feeling abnormal—Etoposide—sarcoma	9.83e-05	0.0003	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—sarcoma	9.82e-05	0.000299	CcSEcCtD
Bortezomib—Diarrhoea—Mitoxantrone—sarcoma	9.81e-05	0.000299	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—sarcoma	9.79e-05	0.000298	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—sarcoma	9.76e-05	0.000297	CcSEcCtD
Bortezomib—Gastrointestinal pain—Etoposide—sarcoma	9.76e-05	0.000297	CcSEcCtD
Bortezomib—Dizziness—Vincristine—sarcoma	9.74e-05	0.000297	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—sarcoma	9.7e-05	0.000296	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—sarcoma	9.7e-05	0.000296	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	9.62e-05	0.000293	CcSEcCtD
Bortezomib—Bradycardia—Epirubicin—sarcoma	9.58e-05	0.000292	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—sarcoma	9.54e-05	0.000291	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—sarcoma	9.51e-05	0.00029	CcSEcCtD
Bortezomib—Urticaria—Etoposide—sarcoma	9.48e-05	0.000289	CcSEcCtD
Bortezomib—Haemoglobin—Epirubicin—sarcoma	9.46e-05	0.000288	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—sarcoma	9.46e-05	0.000288	CcSEcCtD
Bortezomib—Abdominal pain—Etoposide—sarcoma	9.43e-05	0.000287	CcSEcCtD
Bortezomib—Body temperature increased—Etoposide—sarcoma	9.43e-05	0.000287	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—sarcoma	9.43e-05	0.000287	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—sarcoma	9.43e-05	0.000287	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—sarcoma	9.41e-05	0.000287	CcSEcCtD
Bortezomib—Haemorrhage—Epirubicin—sarcoma	9.41e-05	0.000287	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—sarcoma	9.37e-05	0.000285	CcSEcCtD
Bortezomib—Vomiting—Vincristine—sarcoma	9.36e-05	0.000285	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—sarcoma	9.3e-05	0.000283	CcSEcCtD
Bortezomib—Rash—Vincristine—sarcoma	9.29e-05	0.000283	CcSEcCtD
Bortezomib—Dermatitis—Vincristine—sarcoma	9.28e-05	0.000283	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—sarcoma	9.27e-05	0.000283	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—sarcoma	9.25e-05	0.000282	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—sarcoma	9.25e-05	0.000282	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—sarcoma	9.23e-05	0.000281	CcSEcCtD
Bortezomib—Headache—Vincristine—sarcoma	9.23e-05	0.000281	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—sarcoma	9.18e-05	0.00028	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—sarcoma	9.15e-05	0.000279	CcSEcCtD
Bortezomib—Vomiting—Mitoxantrone—sarcoma	9.12e-05	0.000278	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—sarcoma	9.1e-05	0.000277	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—sarcoma	9.07e-05	0.000276	CcSEcCtD
Bortezomib—Rash—Mitoxantrone—sarcoma	9.04e-05	0.000276	CcSEcCtD
Bortezomib—Dermatitis—Mitoxantrone—sarcoma	9.04e-05	0.000275	CcSEcCtD
Bortezomib—Headache—Mitoxantrone—sarcoma	8.99e-05	0.000274	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—sarcoma	8.9e-05	0.000271	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—sarcoma	8.87e-05	0.00027	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—sarcoma	8.8e-05	0.000268	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—sarcoma	8.79e-05	0.000268	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—sarcoma	8.78e-05	0.000267	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—sarcoma	8.75e-05	0.000267	CcSEcCtD
Bortezomib—Nausea—Vincristine—sarcoma	8.75e-05	0.000267	CcSEcCtD
Bortezomib—Flushing—Epirubicin—sarcoma	8.74e-05	0.000266	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—sarcoma	8.74e-05	0.000266	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—sarcoma	8.71e-05	0.000265	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—sarcoma	8.71e-05	0.000265	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—sarcoma	8.67e-05	0.000264	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—sarcoma	8.6e-05	0.000262	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—sarcoma	8.58e-05	0.000261	CcSEcCtD
Bortezomib—Asthenia—Etoposide—sarcoma	8.56e-05	0.000261	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—sarcoma	8.56e-05	0.000261	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—sarcoma	8.54e-05	0.00026	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—sarcoma	8.54e-05	0.00026	CcSEcCtD
Bortezomib—Nausea—Mitoxantrone—sarcoma	8.52e-05	0.00026	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—sarcoma	8.5e-05	0.000259	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—sarcoma	8.48e-05	0.000259	CcSEcCtD
Bortezomib—Chills—Epirubicin—sarcoma	8.45e-05	0.000257	CcSEcCtD
Bortezomib—Pruritus—Etoposide—sarcoma	8.44e-05	0.000257	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—sarcoma	8.41e-05	0.000256	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—sarcoma	8.39e-05	0.000256	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—sarcoma	8.25e-05	0.000251	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—sarcoma	8.24e-05	0.000251	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—sarcoma	8.19e-05	0.00025	CcSEcCtD
Bortezomib—Erythema—Epirubicin—sarcoma	8.19e-05	0.00025	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—sarcoma	8.16e-05	0.000249	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—sarcoma	8.14e-05	0.000248	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—sarcoma	8.12e-05	0.000247	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—sarcoma	8.08e-05	0.000246	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—sarcoma	8.08e-05	0.000246	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—sarcoma	8.07e-05	0.000246	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—sarcoma	8.02e-05	0.000245	CcSEcCtD
Bortezomib—Back pain—Epirubicin—sarcoma	7.93e-05	0.000242	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—sarcoma	7.9e-05	0.000241	CcSEcCtD
Bortezomib—Dizziness—Etoposide—sarcoma	7.89e-05	0.00024	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—sarcoma	7.88e-05	0.00024	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—sarcoma	7.87e-05	0.00024	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—sarcoma	7.85e-05	0.000239	CcSEcCtD
Bortezomib—Chills—Doxorubicin—sarcoma	7.82e-05	0.000238	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—sarcoma	7.78e-05	0.000237	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—sarcoma	7.72e-05	0.000235	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—sarcoma	7.63e-05	0.000233	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—sarcoma	7.6e-05	0.000232	CcSEcCtD
Bortezomib—Vomiting—Etoposide—sarcoma	7.59e-05	0.000231	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—sarcoma	7.58e-05	0.000231	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—sarcoma	7.58e-05	0.000231	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—sarcoma	7.57e-05	0.000231	CcSEcCtD
Bortezomib—Agitation—Epirubicin—sarcoma	7.53e-05	0.000229	CcSEcCtD
Bortezomib—Rash—Etoposide—sarcoma	7.52e-05	0.000229	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—sarcoma	7.52e-05	0.000229	CcSEcCtD
Bortezomib—Headache—Etoposide—sarcoma	7.47e-05	0.000228	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—sarcoma	7.47e-05	0.000228	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—sarcoma	7.43e-05	0.000226	CcSEcCtD
Bortezomib—Malaise—Epirubicin—sarcoma	7.39e-05	0.000225	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—sarcoma	7.36e-05	0.000224	CcSEcCtD
Bortezomib—Syncope—Epirubicin—sarcoma	7.35e-05	0.000224	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—sarcoma	7.34e-05	0.000224	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—sarcoma	7.33e-05	0.000223	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—sarcoma	7.29e-05	0.000222	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—sarcoma	7.24e-05	0.000221	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—sarcoma	7.2e-05	0.000219	CcSEcCtD
Bortezomib—Cough—Epirubicin—sarcoma	7.15e-05	0.000218	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—sarcoma	7.15e-05	0.000218	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—sarcoma	7.1e-05	0.000216	CcSEcCtD
Bortezomib—Nausea—Etoposide—sarcoma	7.09e-05	0.000216	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—sarcoma	7.07e-05	0.000216	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—sarcoma	7.04e-05	0.000214	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—sarcoma	7.01e-05	0.000214	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—sarcoma	6.98e-05	0.000213	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—sarcoma	6.98e-05	0.000213	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—sarcoma	6.98e-05	0.000213	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—sarcoma	6.97e-05	0.000212	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—sarcoma	6.95e-05	0.000212	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	6.93e-05	0.000211	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—sarcoma	6.89e-05	0.00021	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—sarcoma	6.84e-05	0.000208	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—sarcoma	6.81e-05	0.000208	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—sarcoma	6.8e-05	0.000207	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—sarcoma	6.79e-05	0.000207	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—sarcoma	6.74e-05	0.000205	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—sarcoma	6.7e-05	0.000204	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—sarcoma	6.69e-05	0.000204	CcSEcCtD
Bortezomib—Oedema—Epirubicin—sarcoma	6.69e-05	0.000204	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—sarcoma	6.66e-05	0.000203	CcSEcCtD
Bortezomib—Infection—Epirubicin—sarcoma	6.64e-05	0.000202	CcSEcCtD
Bortezomib—Cough—Doxorubicin—sarcoma	6.62e-05	0.000202	CcSEcCtD
Bortezomib—Shock—Epirubicin—sarcoma	6.58e-05	0.0002	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—sarcoma	6.57e-05	0.0002	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—sarcoma	6.56e-05	0.0002	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—sarcoma	6.55e-05	0.0002	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—sarcoma	6.55e-05	0.000199	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—sarcoma	6.53e-05	0.000199	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—sarcoma	6.5e-05	0.000198	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—sarcoma	6.47e-05	0.000197	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—sarcoma	6.46e-05	0.000197	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—sarcoma	6.46e-05	0.000197	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—sarcoma	6.46e-05	0.000197	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—sarcoma	6.43e-05	0.000196	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	6.41e-05	0.000195	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—sarcoma	6.38e-05	0.000194	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—sarcoma	6.38e-05	0.000194	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—sarcoma	6.25e-05	0.00019	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—sarcoma	6.24e-05	0.00019	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—sarcoma	6.19e-05	0.000189	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—sarcoma	6.19e-05	0.000189	CcSEcCtD
Bortezomib—Infection—Doxorubicin—sarcoma	6.15e-05	0.000187	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—sarcoma	6.09e-05	0.000186	CcSEcCtD
Bortezomib—Shock—Doxorubicin—sarcoma	6.09e-05	0.000186	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—sarcoma	6.07e-05	0.000185	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—sarcoma	6.06e-05	0.000185	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—sarcoma	6.05e-05	0.000184	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—sarcoma	6.04e-05	0.000184	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—sarcoma	6.01e-05	0.000183	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—sarcoma	6.01e-05	0.000183	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—sarcoma	5.98e-05	0.000182	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—sarcoma	5.96e-05	0.000182	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—sarcoma	5.9e-05	0.00018	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—sarcoma	5.89e-05	0.000179	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—sarcoma	5.81e-05	0.000177	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—sarcoma	5.78e-05	0.000176	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—sarcoma	5.77e-05	0.000176	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—sarcoma	5.77e-05	0.000176	CcSEcCtD
Bortezomib—Pain—Epirubicin—sarcoma	5.72e-05	0.000174	CcSEcCtD
Bortezomib—Constipation—Epirubicin—sarcoma	5.72e-05	0.000174	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—sarcoma	5.64e-05	0.000172	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—sarcoma	5.6e-05	0.000171	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—sarcoma	5.56e-05	0.000169	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—sarcoma	5.52e-05	0.000168	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—sarcoma	5.51e-05	0.000168	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—sarcoma	5.47e-05	0.000167	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—sarcoma	5.45e-05	0.000166	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—sarcoma	5.38e-05	0.000164	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—sarcoma	5.34e-05	0.000163	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—sarcoma	5.34e-05	0.000163	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—sarcoma	5.31e-05	0.000162	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—sarcoma	5.29e-05	0.000161	CcSEcCtD
Bortezomib—Pain—Doxorubicin—sarcoma	5.29e-05	0.000161	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—sarcoma	5.29e-05	0.000161	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—sarcoma	5.29e-05	0.000161	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—sarcoma	5.1e-05	0.000155	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—sarcoma	5.06e-05	0.000154	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—sarcoma	4.93e-05	0.00015	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—sarcoma	4.92e-05	0.00015	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—sarcoma	4.89e-05	0.000149	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—sarcoma	4.89e-05	0.000149	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—sarcoma	4.8e-05	0.000146	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—sarcoma	4.73e-05	0.000144	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—sarcoma	4.58e-05	0.000139	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—sarcoma	4.56e-05	0.000139	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—sarcoma	4.44e-05	0.000135	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—sarcoma	4.42e-05	0.000135	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—sarcoma	4.38e-05	0.000133	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—sarcoma	4.25e-05	0.00013	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—sarcoma	4.23e-05	0.000129	CcSEcCtD
Bortezomib—Rash—Epirubicin—sarcoma	4.22e-05	0.000128	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—sarcoma	4.21e-05	0.000128	CcSEcCtD
Bortezomib—Headache—Epirubicin—sarcoma	4.19e-05	0.000128	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—sarcoma	4.09e-05	0.000125	CcSEcCtD
Bortezomib—Nausea—Epirubicin—sarcoma	3.97e-05	0.000121	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—sarcoma	3.93e-05	0.00012	CcSEcCtD
Bortezomib—Rash—Doxorubicin—sarcoma	3.9e-05	0.000119	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—sarcoma	3.9e-05	0.000119	CcSEcCtD
Bortezomib—Headache—Doxorubicin—sarcoma	3.88e-05	0.000118	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—sarcoma	3.68e-05	0.000112	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—PDGFRA—sarcoma	3.08e-05	0.000176	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CTNNB1—sarcoma	3.06e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—KRAS—sarcoma	3.05e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CTNNB1—sarcoma	3.04e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PDGFRA—sarcoma	3.04e-05	0.000173	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CTNNB1—sarcoma	3.03e-05	0.000173	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—sarcoma	3.01e-05	0.000171	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—sarcoma	3.01e-05	0.000171	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—sarcoma	3.01e-05	0.000171	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CREB1—sarcoma	3e-05	0.000171	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—SRC—sarcoma	2.99e-05	0.000171	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CREB1—sarcoma	2.99e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—SRC—sarcoma	2.98e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CREB1—sarcoma	2.97e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—SRC—sarcoma	2.97e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—sarcoma	2.96e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MDM2—sarcoma	2.91e-05	0.000166	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MDM2—sarcoma	2.91e-05	0.000166	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MDM2—sarcoma	2.91e-05	0.000166	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—NRAS—sarcoma	2.88e-05	0.000164	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MDM2—sarcoma	2.87e-05	0.000164	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NRAS—sarcoma	2.87e-05	0.000164	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NRAS—sarcoma	2.85e-05	0.000163	CbGpPWpGaD
Bortezomib—PSMA1—Disease—SRC—sarcoma	2.76e-05	0.000158	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PLCG1—sarcoma	2.76e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMD1—Disease—SRC—sarcoma	2.75e-05	0.000157	CbGpPWpGaD
Bortezomib—PSMD2—Disease—SRC—sarcoma	2.74e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MDM2—sarcoma	2.69e-05	0.000153	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MDM2—sarcoma	2.69e-05	0.000153	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MDM2—sarcoma	2.69e-05	0.000153	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—MYC—sarcoma	2.67e-05	0.000152	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NRAS—sarcoma	2.66e-05	0.000152	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—MYC—sarcoma	2.66e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MDM2—sarcoma	2.65e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NRAS—sarcoma	2.65e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—MYC—sarcoma	2.64e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMD2—Disease—NRAS—sarcoma	2.63e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—sarcoma	2.63e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—sarcoma	2.63e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—sarcoma	2.63e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EGFR—sarcoma	2.62e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EGFR—sarcoma	2.61e-05	0.000149	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL2—sarcoma	2.6e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL2—sarcoma	2.6e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL2—sarcoma	2.6e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EGFR—sarcoma	2.6e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—sarcoma	2.6e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KDR—sarcoma	2.59e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KDR—sarcoma	2.59e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KDR—sarcoma	2.59e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—sarcoma	2.56e-05	0.000146	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KDR—sarcoma	2.56e-05	0.000146	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—JUN—sarcoma	2.53e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—JUN—sarcoma	2.53e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—JUN—sarcoma	2.53e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CTNNB1—sarcoma	2.51e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CTNNB1—sarcoma	2.51e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CTNNB1—sarcoma	2.51e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—JUN—sarcoma	2.49e-05	0.000142	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MDM2—sarcoma	2.48e-05	0.000142	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KRAS—sarcoma	2.48e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MYC—sarcoma	2.48e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CTNNB1—sarcoma	2.48e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MDM2—sarcoma	2.47e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KRAS—sarcoma	2.47e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MYC—sarcoma	2.47e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MDM2—sarcoma	2.46e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KRAS—sarcoma	2.46e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MYC—sarcoma	2.45e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EGFR—sarcoma	2.42e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EGFR—sarcoma	2.41e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EGFR—sarcoma	2.4e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KIT—sarcoma	2.39e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KIT—sarcoma	2.39e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KIT—sarcoma	2.39e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KIT—sarcoma	2.36e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CTNNB1—sarcoma	2.32e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CTNNB1—sarcoma	2.32e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CTNNB1—sarcoma	2.32e-05	0.000132	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ENO2—sarcoma	2.29e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KRAS—sarcoma	2.29e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CTNNB1—sarcoma	2.29e-05	0.00013	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HBA1—sarcoma	2.28e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KRAS—sarcoma	2.28e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CREB1—sarcoma	2.27e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CREB1—sarcoma	2.27e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CREB1—sarcoma	2.27e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—SRC—sarcoma	2.27e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—SRC—sarcoma	2.27e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—SRC—sarcoma	2.27e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KRAS—sarcoma	2.27e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CREB1—sarcoma	2.24e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—SRC—sarcoma	2.24e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL2—sarcoma	2.22e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—sarcoma	2.21e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—sarcoma	2.2e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NRAS—sarcoma	2.18e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NRAS—sarcoma	2.18e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NRAS—sarcoma	2.18e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCND1—sarcoma	2.16e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—JUN—sarcoma	2.16e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCND1—sarcoma	2.15e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NRAS—sarcoma	2.15e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—JUN—sarcoma	2.15e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCND1—sarcoma	2.14e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CTNNB1—sarcoma	2.14e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—JUN—sarcoma	2.14e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CTNNB1—sarcoma	2.13e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CTNNB1—sarcoma	2.12e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—sarcoma	2.11e-05	0.00012	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO2—sarcoma	2.1e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—sarcoma	2.1e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB1—Disease—SRC—sarcoma	2.1e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB5—Disease—SRC—sarcoma	2.1e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB2—Disease—SRC—sarcoma	2.1e-05	0.00012	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HBA1—sarcoma	2.09e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—sarcoma	2.09e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB8—Disease—SRC—sarcoma	2.07e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MYC—sarcoma	2.02e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MYC—sarcoma	2.02e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MYC—sarcoma	2.02e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NRAS—sarcoma	2.02e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NRAS—sarcoma	2.02e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NRAS—sarcoma	2.02e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MYC—sarcoma	1.99e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—sarcoma	1.99e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—sarcoma	1.99e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—sarcoma	1.99e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NRAS—sarcoma	1.99e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—sarcoma	1.96e-05	0.000112	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PLCG1—sarcoma	1.95e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—sarcoma	1.95e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—sarcoma	1.94e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SRC—sarcoma	1.94e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—sarcoma	1.93e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SRC—sarcoma	1.93e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SRC—sarcoma	1.92e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—sarcoma	1.89e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MDM2—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MDM2—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MDM2—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO2—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—sarcoma	1.88e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—sarcoma	1.87e-05	0.000107	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HBA1—sarcoma	1.87e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—sarcoma	1.86e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MDM2—sarcoma	1.86e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—sarcoma	1.85e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—sarcoma	1.85e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—sarcoma	1.85e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—sarcoma	1.84e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—sarcoma	1.84e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—sarcoma	1.84e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—sarcoma	1.84e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—sarcoma	1.81e-05	0.000103	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PLCG1—sarcoma	1.78e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—sarcoma	1.73e-05	9.9e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—sarcoma	1.73e-05	9.9e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—sarcoma	1.73e-05	9.9e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—sarcoma	1.73e-05	9.9e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO2—sarcoma	1.73e-05	9.85e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—sarcoma	1.73e-05	9.85e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—sarcoma	1.72e-05	9.8e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HBA1—sarcoma	1.72e-05	9.79e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO2—sarcoma	1.71e-05	9.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—sarcoma	1.71e-05	9.76e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HBA1—sarcoma	1.7e-05	9.71e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—sarcoma	1.7e-05	9.68e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—sarcoma	1.69e-05	9.63e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—sarcoma	1.68e-05	9.59e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—sarcoma	1.68e-05	9.59e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—sarcoma	1.68e-05	9.59e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—sarcoma	1.68e-05	9.59e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—sarcoma	1.66e-05	9.46e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—sarcoma	1.64e-05	9.35e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—sarcoma	1.64e-05	9.35e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—sarcoma	1.64e-05	9.35e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—JUN—sarcoma	1.64e-05	9.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—JUN—sarcoma	1.64e-05	9.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—JUN—sarcoma	1.64e-05	9.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CTNNB1—sarcoma	1.62e-05	9.26e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CTNNB1—sarcoma	1.62e-05	9.26e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CTNNB1—sarcoma	1.62e-05	9.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—sarcoma	1.62e-05	9.22e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—JUN—sarcoma	1.61e-05	9.2e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—sarcoma	1.6e-05	9.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CTNNB1—sarcoma	1.6e-05	9.13e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—sarcoma	1.6e-05	9.11e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—sarcoma	1.6e-05	9.11e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—sarcoma	1.6e-05	9.11e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—sarcoma	1.6e-05	9.1e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PLCG1—sarcoma	1.59e-05	9.09e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—sarcoma	1.59e-05	9.06e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—sarcoma	1.57e-05	8.98e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—sarcoma	1.47e-05	8.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—sarcoma	1.47e-05	8.41e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—sarcoma	1.47e-05	8.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SRC—sarcoma	1.47e-05	8.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SRC—sarcoma	1.47e-05	8.37e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SRC—sarcoma	1.47e-05	8.37e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLCG1—sarcoma	1.47e-05	8.36e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO2—sarcoma	1.46e-05	8.35e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—sarcoma	1.45e-05	8.29e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HBA1—sarcoma	1.45e-05	8.29e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLCG1—sarcoma	1.45e-05	8.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SRC—sarcoma	1.45e-05	8.25e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—sarcoma	1.43e-05	8.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—sarcoma	1.43e-05	8.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—sarcoma	1.43e-05	8.15e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—sarcoma	1.42e-05	8.13e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—sarcoma	1.42e-05	8.09e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—sarcoma	1.41e-05	8.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—sarcoma	1.41e-05	8.05e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—sarcoma	1.41e-05	8.05e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—sarcoma	1.41e-05	8.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—sarcoma	1.41e-05	8.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—sarcoma	1.39e-05	7.94e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—sarcoma	1.36e-05	7.77e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—sarcoma	1.36e-05	7.74e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—sarcoma	1.35e-05	7.7e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—sarcoma	1.31e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—sarcoma	1.31e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—sarcoma	1.31e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—sarcoma	1.3e-05	7.4e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—sarcoma	1.29e-05	7.34e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—sarcoma	1.29e-05	7.34e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—sarcoma	1.29e-05	7.34e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—sarcoma	1.27e-05	7.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLCG1—sarcoma	1.24e-05	7.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—sarcoma	1.21e-05	6.93e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—sarcoma	1.21e-05	6.93e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—sarcoma	1.21e-05	6.93e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—sarcoma	1.2e-05	6.83e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—sarcoma	1.13e-05	6.44e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HBA1—sarcoma	1.12e-05	6.4e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—sarcoma	1.08e-05	6.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—sarcoma	1.08e-05	6.16e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—sarcoma	1.08e-05	6.16e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—sarcoma	1.06e-05	6.07e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—sarcoma	1.03e-05	5.89e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—sarcoma	1.03e-05	5.89e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—sarcoma	1.03e-05	5.89e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—sarcoma	1.02e-05	5.81e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLCG1—sarcoma	9.58e-06	5.47e-05	CbGpPWpGaD
